Kihara James 4

What Happened

• James Kihara, Principal Accounting Officer of ACADIA Pharmaceuticals, had restricted stock units vest on May 1, 2026 (2,596 RSUs converted to shares) and subsequently disposed of shares to cover related tax obligations. A weighted-average open-market sale of 1,332 shares occurred on May 4, 2026, for proceeds of approximately $29,024 (avg. price $21.79; sales ranged $21.79–$21.815). The filings also report a disposition of 2,596 shares at $0 tied to the vesting/withholding process.

Key Details

• Transaction dates and prices:
  • 2026-05-01: RSUs converted to 2,596 shares (conversion/exercise, reported as derivative activity).
  • 2026-05-01: 2,596 shares reported disposed at $0 (tax withholding in connection with RSU vesting).
  • 2026-05-04: Open-market sale of 1,332 shares at a weighted avg price $21.79 (range $21.79–$21.815) for ~$29,024.
• Shares owned after transaction: Not specified in the excerpt of the Form 4 provided.
• Notable footnotes:
  • F1/F4: These were restricted stock units (one RSU = one share) vesting in annual installments (vesting began May 1, 2024).
  • F2: The sales were mandatory to cover withholding taxes related to RSU vesting and intended to comply with Rule 10b5-1(c) requirements.
  • F3: Reported sale price is a weighted average; the filer can provide breakouts by trade price on request.
• Filing timeliness: The Form 4 was filed May 5, 2026 for transactions on May 1 and May 4; no indication in the provided data that the filing was late.

Context

• These transactions are routine for RSU vesting: RSUs converted to shares and a portion of shares were withheld or sold to satisfy tax withholding — not an independent purchase decision signaling bullishness. The derivative-code entries reflect conversion/settlement of RSUs and tax withholding rather than a market-driven bet.